Some CDMOs have also experienced increased demand for certain drug products that have been explored for the treatment of COVID-19 symptoms. They have faced the challenge of meeting this demand while ensuring they can continue to supply other vital medicines to customers.
For example, since the outbreak, Recipharm received higher numbers of requests for antibiotics to treat the secondary bacterial infections in some COVID-19 patients. To meet this demand, we have been taking measures such as increasing the safety stock of both API and raw material, introducing different shift patterns for the existing team and recruiting more personnel where required.
In an article with Pharmaceutical Technology, Recipharm’s Erik Haeffler, Vice President, Manufacturing Services & Head of Sustainability, discusses how COVID-19 has created a rise in demand for outsourced services and the need for CDMOs to re-think their approach to deal with the situation.
If you want to read more about how we are navigating the COVID-19 pandemic, read more here.
The pharmaceutical supply chain has of course been impacted by COVID-19, with common issues including raw material delays and challenges with the shipment of goods. Increased border controls have further exacerbated this issue.
Since the outbreak, Recipharm received higher numbers of requests for antibiotics to treat the secondary bacterial infections in some COVID-19 patients.